Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Roccaro

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
International Journal of Molecular Medicine|March 20, 2001
Coordinate immunoreactivity to vascular endothelial growth factor receptor-2 and its ligand suggests a paracrine regulation during the development of the vascular system in the chick embryo bursa of FabriciusD Ribatti, G De Falco, A Vacca, et al.
Current Pharmaceutical Biotechnology|December 16, 2006
Bortezomib as an antitumor agentA M Roccaro, T Hideshima, P G Richardson, et al.
Neuroscience|May 3, 2006
Increased matrix-metalloproteinase-2 and matrix-metalloproteinase-9 expression in the brain of dystrophic mdx mouseB Nico, P Corsi, R Ria, et al.
Leukemia|October 25, 2016
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myelomaS Manier, J T Powers, A Sacco, et al.
Leukemia|March 28, 2017
Proteomic characterization of human multiple myeloma bone marrow extracellular matrixS V Glavey, A Naba, S Manier, et al.
Leukemia|July 4, 2015
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemiaI M Ghobrial, R Redd, P Armand, et al.
Leukemia|February 10, 2016
Targeting vasculogenesis to prevent progression in multiple myelomaM Moschetta, Y Mishima, Y Kawano, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trialsC S Tam, P Kapoor, J J Castillo, et al.
Current Cancer Drug Targets|January 21, 2011
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsB C Potts, M X Albitar, K C Anderson, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Journal of Molecular Medicine|March 20, 2001
Coordinate immunoreactivity to vascular endothelial growth factor receptor-2 and its ligand suggests a paracrine regulation during the development of the vascular system in the chick embryo bursa of FabriciusD Ribatti, G De Falco, A Vacca, et al.
Current Pharmaceutical Biotechnology|December 16, 2006
Bortezomib as an antitumor agentA M Roccaro, T Hideshima, P G Richardson, et al.
Neuroscience|May 3, 2006
Increased matrix-metalloproteinase-2 and matrix-metalloproteinase-9 expression in the brain of dystrophic mdx mouseB Nico, P Corsi, R Ria, et al.
Leukemia|October 25, 2016
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myelomaS Manier, J T Powers, A Sacco, et al.
Leukemia|March 28, 2017
Proteomic characterization of human multiple myeloma bone marrow extracellular matrixS V Glavey, A Naba, S Manier, et al.
Leukemia|July 4, 2015
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemiaI M Ghobrial, R Redd, P Armand, et al.
Leukemia|February 10, 2016
Targeting vasculogenesis to prevent progression in multiple myelomaM Moschetta, Y Mishima, Y Kawano, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trialsC S Tam, P Kapoor, J J Castillo, et al.
Current Cancer Drug Targets|January 21, 2011
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsB C Potts, M X Albitar, K C Anderson, et al.
Pageof 2